SACRAMENTO, Calif. , Feb. 9, 2026 /PRNewswire/ — Dear Shareholders, We have completed our AI platform in the last 12 months and now it is commercial. NegotiationsSACRAMENTO, Calif. , Feb. 9, 2026 /PRNewswire/ — Dear Shareholders, We have completed our AI platform in the last 12 months and now it is commercial. Negotiations

Lunai Bioworks, Inc. Issues Letter to Shareholders

2026/02/10 00:32
8 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

SACRAMENTO, Calif. , Feb. 9, 2026 /PRNewswire/ —

Dear Shareholders,

We have completed our AI platform in the last 12 months and now it is commercial. Negotiations are moving forward with several pharmaceutical and drug discovery companies. Partnerships and collaborations are imminent. Why? -because Lunai Bioworks operates a closed loop AI system that is truly disruptive (and complementary) to current discovery platforms and that turns complex biology into real-world action in several ways with less cash burn and new revenue streams. Our Augusta platform starts with real biological signals from patients — genetic, molecular, and clinical data — and uses artificial intelligence to reverse-engineer diseases into biologically defined subgroups. Instead of asking, “What drug hits this target?” Lunai asks, “What biology is actually driving this subgroup of patients?”

Then comes the part most AI companies can’t do.

Lunai rapidly tests its predictions in living systems using high-throughput in vivo models. That means its drug ideas aren’t just computer outputs — they’re biologically validated early, before hundreds of millions of dollars are spent. Our approach is designed to shorten pharmaceutical companies’ current drug discovery programs from over 2 years to under a year, same them substantial money, and increase the probability of success.

In short:

Better data → smarter targets → earlier proof → lower risk.

Lunia has established three revenue driven engines

A) AI Drug Discovery: enabling pharmaceutical companies to understand disease biology and design better clinical trials, so promising therapies reach patients faster. We have established new fully owned company technologies for royalty-based partnerships.  While we have been focused on CNS diseases today, we launched a new AI oncology pilot with a clinical-stage partner using our Augusta platform to re-analyze data from a randomized Phase 2 metastatic colorectal cancer survival trial—work that can expand into a broader commercial relationship. We validated the foundation for this project in our work for Northwell Health and J&J (Janssen) using real-world hospital data from severe COVID-19 patients to show that different patient subgroups experience very different outcomes. This program demonstrated that analyzing large clinical datasets can reveal which patients are most likely to benefit from specific treatments, reinforcing the value of Lunai’s precision-medicine approach.

B) AI Bio-Defense discoveries: using AI to detect emerging chemical/biological threats, understand their effects quickly, and help identify effective antidotes and countermeasures. This initiative applied our same technology stack in reverse. We already understand chemical toxicity which we use to screen out potential new drugs. For biodefense we can use our data in combination with other large data sets to identify new chemical weapons, test antidotes in our closed loop in vivo system, and can then identify countermeasures.  Our goal is to monetize this program through government contracts.

C) Immunotherapy: we reported that its next-generation allogeneic dendritic cell (DC) immunotherapy achieved complete regression of both primary and metastatic pancreatic tumors in preclinical humanized mouse models, and that these results were published in a peer-reviewed Brief Report in the journal Vaccines (Nov. 2025). We have recieved an LOI to license the therapy and are currently in discussion with several other companies for licensing other parts of our oncology platform.

Path A: AI Drug Discovery — making clinical trials smarter and more likely to succeed

Despite billions spent every year, drug development still fails more than it succeeds — especially in brain diseases like Alzheimer’s, Parkinson’s, alcohol use disorder, and epilepsy. The traditional model is slow, expensive, and based largely on educated guesswork. Companies pick a target, design a drug, and hope it works in humans years later. Most don’t. The reason that no drugs have worked for what call Alzheimer’s and Parkinsons is that the “one-size-fits-all” drugs were doomed from the start because the assumption was wrong. Each category of these CNS diseases is defined by a collection of different biological subtypes. By standardizing human data, and then using AI to reverse engineer the disease, Lunai traces the biology of each subtype to the related genes and then discovers potential drugs of interest and test them in living systems. We did this for Supernus Pharmaceuticals (NASDAQ: SUPN) by identifying the right epilepsy subgroup for their lead candidate (SPN_817) phase 2 clinical trial. We have recently announced three distinct types of Parkinsons and are working towards commercial deals in Parkinsons and Alzheimer’s.

We announced today that we are also applying our drug discovery platform to cancer through the launch of a new oncology collaboration with a clinical-stage partner to analyze data from a randomized Phase 2 metastatic colorectal cancer trial. Cancer trials are expensive and difficult, and many fail late because the right patients weren’t identified early enough. What we’re doing in the program announced today is straightforward to explain:

We’re using Augusta to learn more from existing clinical trial data—combining patient clinical data, AI-derived imaging signals, and long-term outcomes—to identify which patients benefit most from a new colon cancer drug and why. 

Our technology platform identifies biologically meaningful subgroups that are designed to enable our partner to:

  • enroll the right patients,
  • choose the right endpoints,
  • size trials more accurately,
  • and reduce costly and time consuming late-stage risk in programs targeting FDA submissions.  

This engagement begins as a defined pilot, with a clear path to expand into a multi-study commercial relationship based on results. For Lunai, this is the kind of near-term work that can translate into repeatable revenue while proving out our approach in real-world datasets. 

Path B: AI Bio Defense discoveries, – prevention, response, and countermeasures when time matters

In parallel, Lunai has built a biodefense platform aimed at a hard problem: modern threats can spread quickly, and decision-makers often need answers when information is incomplete.

Our biodefense stack is designed to support the full lifecycle: 

Sentinel (Prevention): AI systems designed to help detect and prevent the misuse of chemical and biological knowledge before harm occurs. 

Pathfinder (Response): rapid assessment of emerging threats—predicting potential toxicity, affected organ systems, and mechanisms of action. 

CounterAct (Countermeasures): identifying and validating antidotes, including rapid repurposing of approved drugs and development of novel countermeasures where none exist. 

Our objective is to help the U.S. and allied stakeholders prepare for elevated geopolitical risk, including the possibility of chemical weapons deployment, and to support evaluation, regulatory pathways, and potential stockpiling of effective countermeasures. 

We are actively in negotiation’s with Government programs and with private-sector partners given the urgency and national security alignment of this work, and we intend to share more details in the near term.  

How these two paths fit together

Both efforts rely on the same core idea: AI should not just generate hypotheses, – we have put AI to work owning serious patents and IP today, so it delivers usable answers:

  • In healthcare: answers and tools that improve trial design and reduce development risk.
  • In biodefense: answers and tools that improve prevention, readiness, response, and treatment options under pressure.

What we’re focused on next (near-term milestones)

Over the coming period, our focus is to:

  1. Advance late-stage commercial discussions across clinical data analytics, precision trial design, and biology-driven discoveries. 
  2. Finalizing biodefense funding conversations and defining the roadmap for Sentinel, Pathfinder, and CounterAct.  
  3. Complete a big new pharma Royalty partnership program on in-house immunotherapy technologies. 

We know many of you have read several Lunai announcements recently. The message we want to leave you with is simple: Lunai has established three immediately scalable revenue generating engines; AI powered drug discovery for CNS diseases and cancer and AI Bio Defense discoveries and tools, each designed for real-world impact, and each capable of creating long-term value and partnerships when implemented and executed with discipline; – our high level focus is driven by one thing only – creating value for our Shareholders. We are trying to fix one of the most expensive problems in medicine using a model that aligns perfectly with how drug development is evolving. When it executes, the gap between what it is today and what it could become is exactly how shareholder value is created.

Thank you for your continued support and confidence in Lunai’s mission for a safer and better future for all. 

Sincerely,

David Weinstein

Chief Executive Officer

Lunai Bioworks, Inc. 

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding potential clinical impact, therapeutic benefit, development timelines, partnering strategy, and commercial value. These statements are subject to risks and uncertainties that may cause actual results to differ materially. Lunai Bioworks undertakes no obligation to update forward-looking statements, except as required by law.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/lunai-bioworks-inc-issues-letter-to-shareholders-302682738.html

SOURCE Lunai Bioworks Inc.

Market Opportunity
Luna by Virtuals Logo
Luna by Virtuals Price(LUNAI)
$0.006838
$0.006838$0.006838
-3.21%
USD
Luna by Virtuals (LUNAI) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Unprecedented Surge: Gold Price Hits Astounding New Record High

Unprecedented Surge: Gold Price Hits Astounding New Record High

BitcoinWorld Unprecedented Surge: Gold Price Hits Astounding New Record High While the world often buzzes with the latest movements in Bitcoin and altcoins, a traditional asset has quietly but powerfully commanded attention: gold. This week, the gold price has once again made headlines, touching an astounding new record high of $3,704 per ounce. This significant milestone reminds investors, both traditional and those deep in the crypto space, of gold’s enduring appeal as a store of value and a hedge against uncertainty. What’s Driving the Record Gold Price Surge? The recent ascent of the gold price to unprecedented levels is not a random event. Several powerful macroeconomic forces are converging, creating a perfect storm for the precious metal. Geopolitical Tensions: Escalating conflicts and global instability often drive investors towards safe-haven assets. Gold, with its long history of retaining value during crises, becomes a preferred choice. Inflation Concerns: Persistent inflation in major economies erodes the purchasing power of fiat currencies. Consequently, investors seek assets like gold that historically maintain their value against rising prices. Central Bank Policies: Many central banks globally are accumulating gold at a significant pace. This institutional demand provides a strong underlying support for the gold price. Furthermore, expectations around interest rate cuts in the future also make non-yielding assets like gold more attractive. These factors collectively paint a picture of a cautious market, where investors are looking for stability amidst a turbulent economic landscape. Understanding Gold’s Appeal in Today’s Market For centuries, gold has held a unique position in the financial world. Its latest record-breaking performance reinforces its status as a critical component of a diversified portfolio. Gold offers a tangible asset that is not subject to the same digital vulnerabilities or regulatory shifts that can impact cryptocurrencies. While digital assets offer exciting growth potential, gold provides a foundational stability that appeals to a broad spectrum of investors. Moreover, the finite supply of gold, much like Bitcoin’s capped supply, contributes to its perceived value. The current market environment, characterized by economic uncertainty and fluctuating currency values, only amplifies gold’s intrinsic benefits. It serves as a reliable hedge when other asset classes, including stocks and sometimes even crypto, face downward pressure. How Does This Record Gold Price Impact Investors? A soaring gold price naturally raises questions for investors. For those who already hold gold, this represents a significant validation of their investment strategy. For others, it might spark renewed interest in this ancient asset. Benefits for Investors: Portfolio Diversification: Gold often moves independently of other asset classes, offering crucial diversification benefits. Wealth Preservation: It acts as a robust store of value, protecting wealth against inflation and economic downturns. Liquidity: Gold markets are highly liquid, allowing for relatively easy buying and selling. Challenges and Considerations: Opportunity Cost: Investing in gold means capital is not allocated to potentially higher-growth assets like equities or certain cryptocurrencies. Volatility: While often seen as stable, gold prices can still experience significant fluctuations, as evidenced by its rapid ascent. Considering the current financial climate, understanding gold’s role can help refine your overall investment approach. Looking Ahead: The Future of the Gold Price What does the future hold for the gold price? While no one can predict market movements with absolute certainty, current trends and expert analyses offer some insights. Continued geopolitical instability and persistent inflationary pressures could sustain demand for gold. Furthermore, if global central banks continue their gold acquisition spree, this could provide a floor for prices. However, a significant easing of inflation or a de-escalation of global conflicts might reduce some of the immediate upward pressure. Investors should remain vigilant, observing global economic indicators and geopolitical developments closely. The ongoing dialogue between traditional finance and the emerging digital asset space also plays a role. As more investors become comfortable with both gold and cryptocurrencies, a nuanced understanding of how these assets complement each other will be crucial for navigating future market cycles. The recent surge in the gold price to a new record high of $3,704 per ounce underscores its enduring significance in the global financial landscape. It serves as a powerful reminder of gold’s role as a safe haven asset, a hedge against inflation, and a vital component for portfolio diversification. While digital assets continue to innovate and capture headlines, gold’s consistent performance during times of uncertainty highlights its timeless value. Whether you are a seasoned investor or new to the market, understanding the drivers behind gold’s ascent is crucial for making informed financial decisions in an ever-evolving world. Frequently Asked Questions (FAQs) Q1: What does a record-high gold price signify for the broader economy? A record-high gold price often indicates underlying economic uncertainty, inflation concerns, and geopolitical instability. Investors tend to flock to gold as a safe haven when they lose confidence in traditional currencies or other asset classes. Q2: How does gold compare to cryptocurrencies as a safe-haven asset? Both gold and some cryptocurrencies (like Bitcoin) are often considered safe havens. Gold has a centuries-long history of retaining value during crises, offering tangibility. Cryptocurrencies, while newer, offer decentralization and can be less susceptible to traditional financial system failures, but they also carry higher volatility and regulatory risks. Q3: Should I invest in gold now that its price is at a record high? Investing at a record high requires careful consideration. While the price might continue to climb due to ongoing market conditions, there’s also a risk of a correction. It’s crucial to assess your personal financial goals, risk tolerance, and consider diversifying your portfolio rather than putting all your capital into a single asset. Q4: What are the main factors that influence the gold price? The gold price is primarily influenced by global economic uncertainty, inflation rates, interest rate policies by central banks, the strength of the U.S. dollar, and geopolitical tensions. Demand from jewelers and industrial uses also play a role, but investment and central bank demand are often the biggest drivers. Q5: Is gold still a good hedge against inflation? Historically, gold has proven to be an effective hedge against inflation. When the purchasing power of fiat currencies declines, gold tends to hold its value or even increase, making it an attractive asset for preserving wealth during inflationary periods. To learn more about the latest crypto market trends, explore our article on key developments shaping Bitcoin’s price action. This post Unprecedented Surge: Gold Price Hits Astounding New Record High first appeared on BitcoinWorld.
Share
Coinstats2025/09/18 02:30
Ripple pushes urgent XRPL patch — but nodes must trust its new key

Ripple pushes urgent XRPL patch — but nodes must trust its new key

The post Ripple pushes urgent XRPL patch — but nodes must trust its new key appeared on BitcoinEthereumNews.com. Ripple has released its fix for public-facing nodes
Share
BitcoinEthereumNews2026/03/14 03:04
Norwegian Krone hobbles ahead of uncertain Norges Bank decision

Norwegian Krone hobbles ahead of uncertain Norges Bank decision

The post Norwegian Krone hobbles ahead of uncertain Norges Bank decision appeared on BitcoinEthereumNews.com. The Norwegian Krone (NOK) remains in the spotlight ahead of the decisive Norges Bank interest rate decision scheduled for Thursday at 08:00 GMT. The EUR/NOK pair is trading around 11.60, up 0.3% on the day, after hitting 11.54 last week, its lowest level in three months. While the consensus is still for a 25 basis points rate cut to 4.00%, uncertainty remains high, fuelled by persistent core inflation at 3.1% and a solid economic outlook. This meeting, accompanied by the publication of the monetary policy report, could provoke a strong market reaction, as Norges Bank is renowned for its surprise decisions. A monetary dilemma for Norway Norway’s macroeconomic signals are confusing. On the one hand, inflation remains well above the central bank’s 2% target, with a technical adjustment that puts core inflation even closer to 3.5% than officially announced. “Altogether, today’s [inflation] figures were stronger than expected… This raises questions about whether Norges Bank will deliver a cut next week”, wrote Handelsbanken in a note relayed by Reuters, following the publication of Norway’s inflation data last week. The strength of the economy reinforces these doubts. Second-quarter Gross Domestic Product (GDP) grew by 0.6% against expectations of 0.3%, while the latest survey by Norges Bank’s regional network confirmed a stable growth outlook. “The central bank is not facing a continental economy in urgent need of easing,” observes Emil Lundh of MNI Markets, who favors a status quo by the central bank. However, other institutions still consider easing likely. ING believes that “despite sticky inflation and a solid outlook, we are still leaning towards a cut to 4.0%”, stresses FX strategist Francesco Pesole. TD Securities even speaks of a “hawkish cut”, underlining the likelihood of the decision being accompanied by a restrictive outlook to limit the impact on the NOK. The Oil…
Share
BitcoinEthereumNews2025/09/18 03:38